WC
VRTX icon

Wexford Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Wexford Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,800
Closed -$361K – 195
2017
Q2 		$361K Buy
+2,800
New +$337K 0.03% 130
2013
Q4 		– Sell
-3,500
Closed -$265K – 273
2013
Q3 		$265K Buy
+3,500
New +$279K 0.02% 185

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wexford Capital's VRTX Position: Q3 2017 in Review

Wexford Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 2,800 shares — an estimated $361K sold.

Wexford Capital first reported a position in VRTX in Q3 2013 and held it in 2 quarters. The position peaked at $361K in Q2 2017. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • Wexford Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Wexford Capital sold 2,800 Vertex Pharmaceuticals shares in Q3 2017, an estimated $361K.
  • Wexford Capital first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Wexford Capital's Vertex Pharmaceuticals position peaked at $361K in Q2 2017.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.